Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : NEOTHERAPEUTICS (NEOT) (NEOTW) -- Ignore unavailable to you. Want to Upgrade?

To: Ironyman who wrote (658)	4/22/1999 11:12:00 AM
From: Marty	Read Replies (1) \| Respond to of 705

How else do you expect them to finance further testing without giving equity options on the loan? You know of anybody willing to finance drug testing without requiring equity options? You know the terms of the loans? As a matter of fact, in this particular circumstance, additional financing is good news because that means the testing is going well. If there was bad or even marginal news from the tests, there would be no reason to borrow money to expand and accelerate the additional tests. The lenders would not even make the loan, no matter how much equity they could get, unless there were positive results in the tests so far. In what way is this a "pattern"? If I were you and I saw a "pattern" of management doing some kind of unspecified "walking it up" to "dump" bad news on the shareholders, I would sell my shares and go short. Alternatively, you could take the trouble to go to their web site and actually find out the potential of the drugs they have in development and what is actually going on.